Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Reports

Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression

Injune Kim, Sang-Ok Moon, Sung Kwang Park, Soo Wan Chae, Gou Young Koh
Download PDF
https://doi.org/10.1161/hh1801.097034
Circulation Research. 2001;89:477-479
Originally published September 14, 2001
Injune Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sang-Ok Moon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung Kwang Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soo Wan Chae
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gou Young Koh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) are potent vasculogenic and angiogenic factors that hold promise as a means to produce therapeutic vascularization and angiogenesis. However, VEGF also acts as a proinflammatory cytokine by inducing adhesion molecules that bind leukocytes to endothelial cells, an initial and essential step toward inflammation. In the present study, we used human umbilical vascular endothelial cells (HUVECs) to examine the effect of Ang1 on VEGF-induced expression of three adhesion molecules: intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. Interestingly, Ang1 suppressed VEGF-induced expression of these adhesion molecules. Furthermore, Ang1 reduced VEGF-induced leukocyte adhesion to HUVECs. These results demonstrate that Ang1 counteracts VEGF-induced inflammation by reducing VEGF-induced endothelial adhesiveness.

  • vascular endothelial growth factor
  • angiopoietin
  • adhesion
  • inflammation

Two endothelial cell–specific growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1), act cooperatively and interactively during prenatal and postnatal vascular development.1 In fact, co-overexpression of VEGF and Ang1 in mouse skin or rabbit ischemic hindlimb produces an additive increase in vessel formation.2,3 Although overexpression of VEGF alone in mouse skin produced profound angiogenesis, it also produced enhanced leukocyte rolling and adhesion, vascular leakage, and inflammation.2,4 Thus, VEGF is also a proinflammatory cytokine in addition to being an angiogenic factor. However, co-overexpression of VEGF and Ang1 in mouse skin showed less vascular leakage and inflammation compared with VEGF alone.2 These data clearly indicate that Ang1 counteracts some subset of activities of VEGF in endothelial cells.

We recently demonstrated that VEGF stimulates the expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin mRNAs in endothelial cells through the Flk-1/KDR receptor.5 This stimulation is mediated through nuclear factor-κB (NF-κB) activation and is suppressed by phosphatidylinositol (PI) 3′-kinase.5 Other studies have shown that Ang1 strongly activates the PI 3′-kinase/Akt pathway in endothelial cells through its binding to the Tie2 receptor.6,7 Therefore, in this study, we assessed the specific role of Ang1 in VEGF-induced expression of adhesion molecules in endothelial cells. Interestingly, our results indicate that Ang1 counteracts VEGF-induced expression and activity of adhesion molecules.

Materials and Methods

Ang1*, rTie1-Fc, and rTie2-Fc were obtained from Regeneron Pharmaceuticals, Inc. Ang1* is a recombinant version of Ang1. Recombinant human VEGF165 was purchased from R&D Systems. Human umbilical vascular endothelial cells (HUVECs) were prepared and maintained as previously described.6

RNase protection assay (RPA), Western blot analyses, and flow cytometric analyses for human ICAM-1, VCAM-1, and E-selectin were performed as previously described.5 Leukocyte-endothelial adhesion was measured as previously described.5

All signals were visualized and analyzed by densitometric scanning (LAS-1000, Fuji Film). Data are expressed as mean±SD. Statistical significance was tested using 1-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at P<0.05.

An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.

Results and Discussion

We developed a method of RPA by which we can simultaneously detect the mRNA levels of ICAM-1, VCAM-1, E-selectin, and cyclophilin. Because VEGF produces a maximum effect at 4 hours on expression of these adhesion molecules,5 we examined the effect of VEGF at this time point. VEGF stimulated expression of these adhesion molecules in a dose-dependent manner (Figure 1A). Ang1 (200 ng/mL) inhibited ≈23% to 29%, 46% to 48%, and 62% to 68% of the VEGF-induced ICAM-1, VCAM-1, and E-selectin mRNAs, respectively, at 4 hours and 6 hours, whereas Ang1 (200 ng/mL) by itself did not produce any significant effect on mRNA levels of these adhesion molecules (Figure 1B). A 5-fold molar excess of rTie2-Fc, but not rTie1-Fc, mostly blocked Ang1-induced suppression of VEGF-induced mRNA of adhesion molecules (Figure 1C). These results indicate that Ang1 exerts its effects on endothelial cells through mainly Tie2 receptor binding, but not through Tie1.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Ang1 suppresses VEGF-induced mRNA levels of ICAM-1, VCAM-1, and E-selectin in HUVECs. A, HUVECs were incubated for 4 hours with the indicated dose of VEGF165. Yeast total RNA (10 μg) was similarly assayed in the presence of RNase (T). To clarify the identity of the bands, ICAM-1 (I), VCAM-1 (V), and E-selectin (E) probes were applied individually to the total RNA from HUVECs treated with VEGF for 4 hours to reveal protected bands of 367, 279, and 187 bp, respectively. B, HUVECs were incubated for 4 hours and 6 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV). C, HUVECs were incubated for 4 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV) with or without 5-fold molar excess of rTie2-Fc (T2) or rTie1-Fc (T1). D, HUVECs were incubated for 4 hours with control buffer (CB), wortmannin (WT, 30 nmol/L), VEGF165 (VE, 20 ng/mL), wortmannin plus VEGF165 (WV), Ang1 plus VEGF165 (AV), or Ang1 plus VEGF165 plus wortmannin (AVW). Total RNAs (10 μg) were subjected to multiplex RPA probed with 4 antisense RNAs: ICAM-1, VCAM-1, E-selectin, and cyclophilin. Bottom panels, Densitometric analyses are presented as the relative ratio of ICAM-1, VCAM-1, or E-selectin mRNA to cyclophilin mRNA. The relative ratio measured in the CB is arbitrarily presented as 1. Bars represent the mean±SD from 4 experiments. *P<0.05 vs 0 ng/mL of VEGF165 or CB; +P<0.05 vs VE; and #P<0.05 vs AV.

We previously demonstrated that VEGF stimulated the expression of ICAM-1, VCAM-1, and E-selectin mRNAs mainly through activation of phospholipase-Cγ and NF-κB.5 This induction was suppressed by activation of PI 3′-kinase.5 Because Ang1 is a strong activator of the intracellular PI 3′-kinase/Akt signaling system,6,7 Ang1-induced activation of PI 3′-kinase/Akt could be the main pathway for suppressing the VEGF-induced expression of adhesion molecules. As we expected, suppression of basal PI 3′-kinase by the pharmacological inhibitor wortmannin (30 nmol/L) induced expression of adhesion molecules (Figure 1D). Furthermore, addition of wortmannin (30 nmol/L) not only enhanced VEGF-induced expression of adhesion molecules but also reversed Ang1-induced suppressive effect on VEGF-induced expression of adhesion molecules (Figure 1D). Addition of another PI 3′-kinase inhibitor, LY294002 (100 nmol/L), produced the same results (data not shown). In fact, our preliminary results indicated that selective activation (or inactivation) of PI 3′-kinase/Akt using adenoviral transfer reduced (or enhanced) VEGF-induced expression of adhesion molecules (data not shown). Thus, Ang1 counteracts VEGF-induced expression of these adhesion molecules, possibly through activation of the PI 3′-kinase/Akt pathway.

We looked further at the protein levels of ICAM-1, VCAM-1, and E-selectin in HUVECs treated with Ang1 and VEGF. Consistent with the RPA data, Ang1 (200 ng/mL) by itself did not produce any significant effect, whereas VEGF (20 ng/mL) increased protein levels at 6 hours (Figure 2). Addition of Ang1 (200 ng/mL) inhibited ≈43%, 44%, and 62% of the VEGF-induced ICAM-1, VCAM-1, and E-selectin protein levels (Figure 2). Using flow cytometry, we also confirmed that Ang1 inhibited VEGF-induced expression of these adhesion molecules on the cell surface of HUVECs (data not shown).

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Ang1 suppresses VEGF-induced protein levels of ICAM-1, VCAM-1, and E-selectin in HUVECs. HUVECs were incubated for 6 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV). Each lane contains 50 μg of total protein from the cells. A through C, Western blots were probed with appropriate antibody (top panels). The blots were reprobed with an anti–actin antibody (bottom panels). D, Densitometric analyses are presented as the relative ratio of ICAM-1:actin, VCAM-1:actin, and E-selectin:actin. The relative ratio in the CB is arbitrarily presented as 1. Bars represent the mean±SD from 5 experiments. *P<0.05 vs CB; +P<0.05 vs VE.

Because the induction of adhesion molecules in endothelial cells induces leukocyte adhesion, we examined whether Ang1 reduces VEGF-induced leukocyte adhesion to HUVECs. Ang1 (200 ng/mL) by itself did not produce any effect, whereas VEGF (20 ng/mL) produced an increase of ≈2.8-fold in leukocyte adhesion after 8 hours compared with addition of control buffer (Figure 3). Ang1 (200 ng/mL) reduced ≈46% of the VEGF-induced leukocyte adhesion (Figure 3). A 5-fold molar excess of rTie2-Fc, but not rTie1-Fc, completely blocked Ang1-induced suppression of VEGF-induced leukocyte adhesion (Figure 3). These results indicate that Ang1 exerts its effects in endothelial cells through Tie2 receptor binding. Function-blocking antibodies to ICAM-1, VCAM-1, and E-selectin, either singly or as a triple combination, suppressed VEGF-induced leukocyte adhesion to varying extents (Figure 3). These data suggest that VEGF-induced adhesiveness requires combined activity of each of these adhesion molecules, because inhibition of the individual molecules could not completely impair the effects of VEGF.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Ang1 suppresses VEGF-induced HUVEC adhesiveness. A, Representative phase-contrast photographs of leukocyte adhesion to HUVECs. Note that there are more leukocytes in HUVECs treated with VEGF than in those treated with control buffer (CB), Ang1, or Ang1 plus VEGF (A+V). Bar=50 μm. B, Quantification of the leukocyte adhesion to HUVECs. Leukocytes were labeled with Vybrant DiD (Molecular Probes) and added to confluent monolayers of HUVECs, which were treated with and without VEGF165 (20 ng/mL) for 8 hours and were also treated with CB, Ang1 (A1, 200 ng/mL) with or without 5-fold molar excess of rTie2-Fc (Tie2) or rTie1-Fc (Tie1), and anti–ICAM-1 antibody (IA, 10 μg/mL), anti–VCAM-1 antibody (VA, 10 μg/mL), anti–E-selectin antibody (SA, 10 μg/mL), or a triple combination of these antibodies (TA). Then, leukocyte adhesion was measured as described in Materials and Methods. Bars represent the mean±SD from 5 experiments. *P<0.05 vs CB; +P<0.05 vs CB plus VEGF165 (20 ng/mL).

To our knowledge, these results are the first to demonstrate that Ang1 can suppress the expression of adhesion molecules. Furthermore, a recent in vitro experiment demonstrated that Ang1 decreases basal and VEGF-induced endothelial permeability.8 Taken together, Ang1 counteracts VEGF-induced inflammation in endothelial cells while having an additive effect on vessel formation.2,3 Therefore, combined treatment with VEGF and Ang1 could be better than sole treatment with one for enhancing therapeutic vascularization and angiogenesis while avoiding inflammation.

Acknowledgments

This work was supported by the Creative Research Initiatives of the Korean Ministry of Science and Technology. We thank Drs John S. Rudge and George D. Yancopoulos for enthusiastic support and for providing angiopoietin- and Tie-related reagents.

Footnotes

  • Original received March 13, 2001; resubmission received May 9, 2001; revised resubmission received July 31, 2001; accepted July 31, 2001.

References

  1. ↵
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407: 242–248.
  2. ↵
    Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999; 286: 2511–2514.
  3. ↵
    Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol. 2000; 20: 2573–2578.
  4. ↵
    Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998; 111: 1–6.
  5. ↵
    Kim I, Moon S-O, Kim SH, Kim HJ, Koh YS, Koh GY. VEGF stimulates expression of ICAM-1, VCAM-1 and E-selectin through nuclear factor-κB activation in endothelial cells. J Biol Chem. 2001; 276: 7614–7620.
  6. ↵
    Kim I, Kim HG, So J-N, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3`-kinase/Akt signal transduction pathway. Circ Res. 2000; 86: 24–29.
  7. ↵
    Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, Altieri DC, Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000; 275: 9102–9105.
  8. ↵
    Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000; 87: 603–607.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
September 14, 2001, Volume 89, Issue 6
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression
    Injune Kim, Sang-Ok Moon, Sung Kwang Park, Soo Wan Chae and Gou Young Koh
    Circulation Research. 2001;89:477-479, originally published September 14, 2001
    https://doi.org/10.1161/hh1801.097034

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression
    Injune Kim, Sang-Ok Moon, Sung Kwang Park, Soo Wan Chae and Gou Young Koh
    Circulation Research. 2001;89:477-479, originally published September 14, 2001
    https://doi.org/10.1161/hh1801.097034
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Mechanisms
    • Vascular Biology
    • Endothelium/Vascular Type/Nitric Oxide
    • Angiogenesis

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured